This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murray, R. M. L. Articles by Pitt, P. Search for Related Content PubMed PubMed Citation Articles by Murray, R. M. L. Articles by Pitt, P.

Hypocalcemic and Normocalcemic Hyperparathyroidism in Patients with Advanced Prostatic Cancer

Peter MacCallum Cancer Institute (R.M.L.M., N.C., J.D., P.P.), Melbourne 3002; and St. Vincent’s Institute of Medical Research (V.G., P.W.M.H.), Melbourne 3065, Australia

Address all correspondence and requests for reprints to: Robin Murray, M.D., Peter MacCallum Cancer Institute, Locked Bag 1, A’Beckett Street, Victoria 8006, Australia.

Abstract

PTH and ionized calcium levels were measured in 131 patients with advanced prostate cancer, all of whom had received at least first-line hormone therapy. Patients were classified into those in remission, those with stable disease, or those with progressive disease according to their prostate-specific antigen response and their clinical status.

Thirty-four percent of all patients had PTH levels above the upper level of normal for controls of similar age (7.0 pmol/liter), and in 44% of these patients this was associated with a normal ionized calcium. Patients with proven bone metastases had significantly higher PTH levels than those without. (7.3 ± 0.5 vs. 4.3 ± 0.4 pmol/liter, P < 0.0005).

There was evidence for a difference in the PTH levels between the three response groups. The PTH levels tended to be higher in patients with progressive disease. Thirty-seven of 65 patients (57%) with both progressive disease and proven bone metastases had elevated PTH levels. Mean levels of urinary deoxypyridinoline and cAMP were significantly greater in patients with high PTH than in those with a normal PTH.

Treatment with oral calcium supplements in 32 patients with a high PTH seemed to have only a transient effect on elevated PTH or low ionized calcium levels.

These data show that secondary hyperparathyroidism occurs frequently in patients with advanced prostate cancer, particularly in those with both progressive disease and bone metastases. The increased PTH levels are associated with an increase in bone resorption markers. These findings raise important questions about the role of PTH in progression of prostatic cancer in bone and the potential limitations of the use of bisphosphonates in patients with a raised PTH or low serum calcium.

This article has been cited by other articles:

				H. G. Skinner and G. G. Schwartz Serum Calcium and Incident and Fatal Prostate Cancer in the National Health and Nutrition Examination Survey Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2302 - 2305. [Abstract] [Full Text] [PDF]

				G. G. Schwartz Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 478 - 483. [Abstract] [Full Text] [PDF]

				G. G. Schwartz, M. C. Hall, D. Stindt, S. Patton, J. Lovato, and F. M. Torti Phase I/II Study of 19-nor-1{alpha}-25-Dihydroxyvitamin D2 (Paricalcitol) in Advanced, Androgen-Insensitive Prostate Cancer Clin. Cancer Res., December 15, 2005; 11(24): 8680 - 8685. [Abstract] [Full Text] [PDF]

				A. Berruti, M. Tucci, C. Terrone, R. M. Scarpa, A. Angeli, and L. Dogliotti Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma J Natl Cancer Inst, February 19, 2003; 95(4): 332 - 333. [Full Text] [PDF]

				R. Vieth Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study Am. J. Clinical Nutrition, August 1, 2002; 76(2): 490 - 491. [Full Text]

				A. Berruti, L. Dogliotti, M. Tucci, R. M. Scarpa, and A. Angeli Hyperparathyroidism Due to the So-Called Bone Hunger Syndrome in Prostate Cancer Patients J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1910 - 1911. [Full Text] [PDF]